11/20
08:07 am
vvos
Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $6.60 price target on the stock.
Medium
Report
Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $6.60 price target on the stock.
11/20
04:42 am
vvos
Rating for VVOS
Medium
Report
Rating for VVOS